Full Range Spectral Domain Anterior Segment OCT Scanner

全范围谱域眼前节 OCT 扫描仪

• 批准号: 7219581
• 负责人: Eric L. Buckland
• 金额: $ 15.5万
• 依托单位: BIOPTIGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-07 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7219581
• 关键词: Animal Experimentation; Animals; Anterior; Applied Research; Arts; Businesses; Class; Clinical; Collaborations; Complex; Computer software; Cornea; Depth; Diagnosis; Endothelium; Equus caballus; Excision; Exhibits; Glaucoma; Hand; Human; Image; Infant; Interferometry; Life; Marketing; Microscope; Morphologic artifacts; Mus; Noise; Operating System; Operative Surgical Procedures; Optical Coherence Tomography; Optics; Patients; Phase; Range; Rate; Research; Resolution; Retinal; Scanning; Signal Transduction; Small Animal Imaging Systems; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Specialist; Speed; Standards of Weights and Measures; Surface; System; Technology; Three-Dimensional Image; Three-Dimensional Imaging; Time; Tissues; Universities; base; corneal epithelium; design; improved; innovation; millimeter; new technology; novel strategies; pre-clinical research; prototype; size

DESCRIPTION (provided by applicant): In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied research applications. OCT is a relatively new technology for ophthalmic imaging, which uses low-coherence interferometry to obtain cross-sectional images in living tissues with micron-scale resolution noninvasively. OCT systems based on the original time-domain interferometry technology have been successfully demonstrated for human retinal and anterior segment imaging at 830nm and 1300nm wavelengths, respectively, however the slower image acquisition rate and lower signal-to-noise ratio of the older technology places severe constraints on the range of subjects which can be successfully imaged. In order to immobilize patients for long acquisition times, retinal and anterior segment OCT imagers commercialized to date have been built into standard tabletop slit-lamp biomicroscope designs. The resulting systems are bulky and limit the range of potential subjects to cooperative humans who can sit upright and fixate well for several seconds. In the last few years, Fourier domain OCT (FDOCT) technology has emerged as a superior alternative to time-domain OCT, exhibiting improved image acquisition speed and robust system design. The increased image acquisition speed opens the possibility for the first time for ophthalmic OCT imaging with handheld probes, and the robust design potential of FDOCT enables the implementation of truly portable systems. Bioptigen, Inc., a startup company affiliated with Duke University, has marketed state-of-the- art retinal FDOCT systems operating at 830nm wavelength using both conventional and handheld delivery optics, and also markets a tabletop microscope-based 1300nm wavelength OCT system for small animal imaging and other pre-clinical research applications. However, due to a limitation intrinsic to FDOCT, both of these systems are limited in imaging depth to less than 4 millimeters, which is insufficient for full-depth anterior segment imaging. In this SBIR Phase I proposal, Bioptigen proposes to adapt their 1300nm OCT and handheld probe technology for high speed, handheld, full-depth anterior segment imaging which will make the benefits of ophthalmic OCT imaging available to a much wider class of subjects, including bedridden and infant human patients, as well as animals of all sizes (from mouse to horse) used in biomedical and veterinary research. In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied research applications. This imaging system will be able to image the full depth of the anterior segment (> 6mm) by developing a novel approach to complex conjugate artifact removal.

描述（由申请人提供）：在这个I期小企业创新研究申请中，Bioptigen公司提出了一种便携式手持式角膜和前段光学相干断层扫描（CAS-OCT）扫描仪的原型，用于临床和应用研究应用。OCT是一项相对较新的眼科成像技术，它使用低相干干涉术以无创的方式获得微米级分辨率的活体组织的横截面图像。基于原始时域干涉技术的OCT系统已经成功地分别用于830nm和1300nm波长的人类视网膜和前段成像，但是旧技术的图像采集速度较慢，信噪比较低，严重限制了可以成功成像的对象范围。为了长时间固定患者，视网膜和前段OCT成像仪已经商业化到目前为止已经内置到标准的桌面裂隙灯生物显微镜设计中。由此产生的系统体积庞大，并且限制了潜在对象的范围，即能够坐直并注视几秒钟的合作人类。在过去的几年中，傅里叶域OCT （FDOCT）技术已经成为时域OCT的优越替代方案，具有改进的图像采集速度和强大的系统设计。图像采集速度的提高首次为手持式探头眼科OCT成像提供了可能，FDOCT强大的设计潜力使实现真正的便携式系统成为可能。Bioptigen, Inc.是一家隶属于杜克大学的初创公司，已经推出了最先进的视网膜FDOCT系统，该系统使用传统和手持传递光学器件，工作在830nm波长，同时还推出了一种基于台式显微镜的1300nm波长OCT系统，用于小动物成像和其他临床前研究应用。然而，由于FDOCT固有的局限性，这两种系统的成像深度都限制在4毫米以下，这不足以进行全深度前段成像。在这项SBIR I期提案中，Bioptigen建议将其1300nm OCT和手持式探针技术应用于高速、手持式、全深度的前段成像，这将使眼科OCT成像的优势适用于更广泛的受试者，包括卧床和婴儿患者，以及用于生物医学和兽医研究的各种大小的动物（从小鼠到马）。在这个第一阶段的小企业创新研究应用中，Bioptigen公司提出了一种便携式手持式角膜和前段光学相干断层扫描（CAS-OCT）扫描仪的原型，用于临床和应用研究。该成像系统通过开发一种去除复杂共轭伪影的新方法，将能够对前段的全深度（bbb6mm）进行成像。